Delivery Order HHSN261201500032I-HHSN26100002
Award Date
9/20/16
Potential Completion Date
6/19/22
Potential Value
$988K
Federal Agency
National Cancer Institute
Ultimate Awardee
Temple University-Of The Commonwealth System Of Higher Education
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Philadelphia, PA 19111, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $547,860 delivery order contract awarded by the National Cancer Institute (NCI) of the Department of Health and Human Services (HHS) to The Institute for Cancer Research, a non-profit research organization. The contract is part of the Preclinical Efficacy and Intermediate Endpoint Biomarkers indefinite delivery vehicle, which supports the PREVENT Cancer Preclinical Drug Development Program. Under this 5-year IDIQ, The Institute for Cancer Research provides preclinical efficacy...
The Institute For Cancer Research, a non-profit subsidiary of Temple University, has been awarded a $884,185.34 firm fixed price delivery order against the National Cancer Institute's PREVENT Cancer Program multiple award indefinite delivery contract vehicle. This delivery order focuses on continued evaluation of candidate chemopreventive and immunopreventive regimens in support of the PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS through...
This federal contract award was issued by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to The Institute for Cancer Research, a non-profit organization and subsidiary of Temple University. The $1,570,991.00 task order is part of the PREVENT Preclinical Drug Development Program, which focuses on preclinical efficacy and intermediate endpoint biomarker testing for cancer prevention drug candidates. The task order is for a project titled...
The National Cancer Institute, a component of the National Institutes of Health within the Department of Health and Human Services, awarded a $1,038,958 Firm Fixed Price Delivery Order to The Institute For Cancer Research Division of Temple University-Of The Commonwealth System Of Higher Education. The Delivery Order was issued against PREVENT Preclinical Drug Development Program Indefinite Delivery Indefinite Quantity Master Contract to fund research on COLORECTAL CANCER PREVENTION BY...
The National Cancer Institute has awarded a $1,237,620.00 firm fixed price delivery order to The Institute for Cancer Research, a non-profit subsidiary of Temple University, to conduct research on "NEXT GENERATION GP130/IL-6/STAT3 INHIBITORS FOR THE PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER." This task order falls under the National Cancer Institute's "PREVENT Preclinical Drug Development Program (PREVENT)" indefinite delivery contract, which focuses on the...
This firm fixed price delivery order contract was awarded to The Institute for Cancer Research, a non-profit subsidiary of Temple University, by the National Cancer Institute (NCI). The contract is a task order under the larger "PREVENT Preclinical Drug Development Program (PREVENT)" indefinite delivery contract, which aims to provide preclinical efficacy and biomarker analysis services to support the evaluation of candidate chemopreventive and immunopreventive regimens. This...
The Institute For Cancer Research (ICR), a non-profit subsidiary of Temple University, was awarded a $779,932 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program (PREVENT) multiple award master indefinite delivery contract held by the National Cancer Institute. The delivery order, with a completion date of March 2025, will fund continued evaluation of candidate chemopreventive and immunopreventive regimens to support the goals of the PREVENT program in...
This is a cost-no-fee delivery order awarded by the National Cancer Institute (NCI) to The Institute for Cancer Research, a non-profit subsidiary of Temple University. The $598,689 contract is for the modulation of cigarette smoke-induced alterations of microRNA expression and lung tumors in mice treated with aspirin and naproxen. This work is being performed under the NCI's Preclinical Efficacy and Intermediate Endpoint Biomarkers multiple-award indefinite delivery contract, which...
This is a firm fixed price delivery order awarded by the National Cancer Institute (NCI) to IIT Research Institute (IITRI), a non-profit preclinical contract research organization (CRO). The contract is for $532,562.26 to evaluate a breast cancer prevention agent under the PREVENT Cancer Preclinical Drug Development Program, a $149.995 million NCI Indefinite Delivery Vehicle (IDV) that IITRI holds. IITRI has extensive experience providing preclinical drug development services to federal...
This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI), a civilian agency, to the University of Oklahoma Health Sciences Center Division as the prime contractor. The task order, valued at $879,465.00, is for research to prevent colorectal cancer using the drug ONC201 alone or in combination with NSAIDs. This task order falls under the NCI's larger PREVENT Preclinical Drug Development Program, which aims to develop new cancer prevention agents. The contract...